Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
12,298 total articles
Nano Labs (NA) is a sub-$50M semiconductor microcap trading at $1.76. Recent product launches, an MOU to explore North American AI data centers, and insider buying provide potential upside triggers. The business is small, illiquid and volatile; this trade is a data-driven, time-boxed swing long (45 trading days) with a tight stop to limit downside.
Sea Limited's $7.1B Q1 revenue (up 47% YoY), first-time adjusted EBITDA north of $1B, and a $1B buyback are the core reasons I'm willing to take a mid-term long trade. Valuation is not cheap, but the business is materially larger (market cap $64.7B) with multiple growth engines — e-commerce, gaming and fintech. Trade plan provided with entry, stop …
Intel has rallied sharply in 2026 but fundamentals tied to data-center revenue growth, 18A process adoption and new foundry customers suggest further upside. Valuation is rich versus history, so this trade uses a disciplined entry at $102.00, a stop at $92.00 and a mid-term target of $125.00 over the next 45 trading days.
Flex is a diversified EMS and manufacturing services company with a fast-growing Cloud and Power Infrastructure (CPI) business that supplies high-density compute, liquid cooling and power-delivery solutions for AI data centers. With a market cap near $44B, free cash flow of $1.05B and a balance sheet that can support strategic separation, the compa…
MTX has delivered consistent revenue growth and improving earnings while trading at a modest multiple (PE ~14, EV/EBITDA ~4.9). Recent operational momentum and capacity investments make the stock a compelling mid-term long. Entry: $72.00, Target: $84.00, Stop: $67.00 (45 trading-day horizon).
CRISPR Therapeutics (CRSP) trades well below its 52-week high after a pullback, offering a high-risk, high-reward long trade. With the company now commercializing Casgevy and a freshly expanded pipeline including CTX611, the next 12 months have clear binary catalysts that could re-rate the stock. This trade idea lays out an entry at $47.48, a disci…
Recent reports that KKR is positioning capital for a stake in SK Telecom’s data center business has the potential to re-rate SKM. Coupled with a major NVIDIA AI cloud partnership, SKM looks attractively priced for a mid-term swing trade targeting a move back toward the $40 area. The setup is actionable but not risk-free; execution, deal terms and m…
AST SpaceMobile's recent $1 billion convertible note offering is the catalyst the company needed to de-risk its path to commercial service. The market punished the stock on the raise, but the capital extends runway, reduces near-term equity dilution pressure and preserves upside if service ramps as planned. We upgrade to a tactical long with an ent…
Delek Logistics offers an attractive 8%+ yield backed by record 2025 adjusted EBITDA, growing third-party revenue, and management guidance that points to stable cash generation. The distribution looks compelling relative to the $2.9B market cap, and recent technicals favor a trade entry near $55.31. The plan below lays out an actionable swing trade…
BlackBerry (BB) has moved from penny nostalgia to a software-driven rebound. With QNX design wins, a near-$1.0B backlog and strategic partnerships (notably NVIDIA), the company has credible revenue growth and cash generation. Price action has pulled back under short-term moving averages, creating a disciplined entry opportunity for investors willin…
Andean Precious Metals (ANPMF) trades at a sub-$700M market cap with a trailing P/E of ~4 and owns a proprietary processing operation at San Bartolomé. The equity looks mispriced relative to its cashflow profile and optionality from tolling and concentrate sales. This is a mid-term swing trade that plays for a re-rate as operational updates and tig…
McDonald's remains structurally advantaged: high-margin franchised model, resilient brand, and a digital + delivery mix that sustains comparable sales and margin. I see a clear trade: buy at pullback near $360 with a $420 target and a $320 stop, horizon focused on operational catalysts and seasonal travel demand.
BlackBerry is trading like a high-growth software name despite most of its revenue being tied to automotive and embedded systems - a cyclical end market. Recent partnerships and a growing design-win backlog support upside to the $12s, but stretched valuation (PE ~90s, market cap ~ $5.2B) and rising short activity demand a tight stop. This trade ide…
Rubrik reported a clean Q1 beat and raised fiscal 2027 guidance, but the stock sits below near-term moving averages and carries elevated short interest. This trade idea offers a disciplined swing entry at $78.20, a $92 target into a retest of the 52-week high zone, and a $70 stop to limit downside while letting the company’s revenue and cash-flow c…
Baytex Energy ($4.20) looks set for a mean-reversion leg after a volatile 12 months. Technicals are constructive, short interest has pulled back from earlier peaks, and a midstream infrastructure deal in Pembina improves take-away optionality. This trade targets a move toward the 52-week high with a defined stop to limit downside.
Netgear trades at sub-1x revenue and roughly 1.3x book while executing a shift from low-margin consumer hardware to higher-margin subscription services and enterprise offerings. With a solid balance sheet, resolving legal overhangs, and product cadence (WiFi 7 mesh + SASE/security push), the risk-reward favors a buy for patient, event-driven invest…
Micron is trading near $866 after a pullback from its spring highs, but fundamentals argue for an upgrade: record-level profitability (EPS $44.69), massive free cash flow ($26.17B), and a fortress-like balance sheet (debt/equity ~0.06) create a pathway to shareholder-friendly capital allocation and a multiple re-rating. That said, aggressive greenf…
Fifth Third's acquisition of Comerica creates a top-10 bank with scale, and the near-term earnings hit from merger costs masks a clear path to margin and expense improvement. I view the stock as a tactical long around $57.45 with a mid-term target of $64.00 and a $51.00 stop while monitoring integration execution and credit trends.
Abercrombie & Fitch (ANF) is trading at a valuation that understates its cash-generation ability and capital return plan. With trailing EPS near $11.11, EV/EBITDA ~4.3 and free cash flow of $416M, ANF looks fundamentally cheap. Recent catalysts - Q1 beat, a Hollister-Target collaboration, and a $450M buyback program - support a mid-term swing trade…
Novo Nordisk's shares look poised to continue higher as the company converts injectables momentum into a dominant oral position. Strong prescription share for the oral Wegovy launch, supportive technicals and a reasonable P/E for a market leader create an actionable long trade with clearly defined risk controls.
Dyne Therapeutics is a buy at current levels based on late-stage progress in Duchenne muscular dystrophy (z-rostudirsen), a growing neuromuscular pipeline and a large cash cushion. The trade is speculative and high-risk: the reward hinges on regulatory success and commercialization execution, while free cash flow burn, crowded competition, and mean…
4D Molecular Therapeutics just cleared several execution hurdles: 2-year PRISM Phase 2b data showed strong durability in wet-AMD, Phase 3 is enrolled, and the company has secured non-dilutive capital while locking APAC commercialization through Otsuka. With a market cap near $590M and a cash cushion from an $85M upfront partner payment plus a $200M…
Itochu is likely to use its upcoming IR Day to sharpen capital-allocation messaging. The company has a strong free-cash-flow profile and a history of shareholder returns; a clear commitment to larger buybacks or accelerated returns would re-rate sentiment. This trade targets an entry at $19.50 with a $23.00 target and a $17.00 stop, for a long-term…
UroGen's Zusduri is moving from clinical novelty to commercial staple. Recent reimbursement wins and a sharp revenue ramp ($51M in Q1; +152% YoY) suggest the therapy is being adopted into urology workflows. Given a market cap near $2.01B and elevated short interest, the setup favors a long trade sized for a mid-to-long-term horizon, with clear entr…
Palantir is trading at $136.20 after strong momentum and accelerating commercial adoption. The company sits at the intersection of large-scale data integration, AI orchestration and mission-critical workflows for government and enterprise clients. Fundamentals show positive free cash flow ($2.69B) and high retention metrics cited by analysts; valua…
